On the Role and Significance of Fas (Apo-1/CD95) Ligand (FasL) Expression in Immune Privileged Tissues and Cancer Cells Using Multiple Myeloma as a Model*

References

• Henkart P. Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity. 1994; 1: 343–346
   PubMed Web of Science ®Google Scholar
• Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–243
   PubMed Web of Science ®Google Scholar
• Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li Weber M., Richards S., Dhein J., Trauth B.C. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 1992; 267: 10709–10715
   PubMed Web of Science ®Google Scholar
• Shima Y., Nashimoto N., Ogata A., Fuji Y., Yoshizaki K., Kishimoto T. Myeloma cells express Fas antigen/Apo-1 (CD-95), but only some are sensitive to anti-Fas-Antibody resulting in apoptosis. Blood 1995; 85: 757–764
   PubMed Web of Science ®Google Scholar
• Nagata S., Goldstein P. The fas death factor. Science 1995; 267: 1499
   Web of Science ®Google Scholar
• Suda T., Takahashi T., Goldstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–1178
   PubMed Web of Science ®Google Scholar
• Pitti R.M, Marsters S.A, Ruppert S., Donahue C.J, Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687–12690
   PubMed Web of Science ®Google Scholar
• Lynch D.H, Ramsdell F., Alderson M.R. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today. 1995; 16: 569–574
   PubMedGoogle Scholar
• Alderson M.R, Tough T.W, Davis Smith T., Braddy S., Falk B., Schooley K.A, Goodwin R.G., Smith C.A, Ramsdell F., Lynch D.H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp. Med. 1995; 181: 71–77
   PubMed Web of Science ®Google Scholar
• Rothstein T.L, Wang J.K, Panka D.J, Foote L.C, Wang Z., Stanger B., Cui H., Ju ST., Marshak Rothstein A. Protection against Fas-dependent Thl-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995; 374: 163–165
   PubMed Web of Science ®Google Scholar
• Rensing Ehl A., Frei K., Flury R., Matiba B., Mariani S.M, Weller M., Aebischer P., Krammer PH., Fontana A. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995; 25: 2253–2258
   PubMed Web of Science ®Google Scholar
• Griffith T.S, Brunner T., Fletcher S.M, Green D.R, Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189–1192
   PubMed Web of Science ®Google Scholar
• Griffith T.S., Ferguson T.A. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997; 18: 240–244
   PubMedGoogle Scholar
• Stuart P.M, Griffith T.S, Usui N., Pepose J., Yu X., Ferguson T.A. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396–402
   PubMed Web of Science ®Google Scholar
• Sonoda Y., Streilein J.W. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation 1992; 54: 694–704
   PubMed Web of Science ®Google Scholar
• Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., Nakao K., Nagata S. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806–3813
   PubMed Web of Science ®Google Scholar
• Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R.C. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630–632
   PubMed Web of Science ®Google Scholar
• Lau H.T, Yu M., Fontana A., Stoeckert C.J, Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109–112
   PubMed Web of Science ®Google Scholar
• Leithauser F., Dhein J., Mechtersheimer G., Koretz K., Bruderlein S., Henne C., Schmidt A., Debatin K.M, Krammer P.H, Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest 1993; 69: 415–429
   PubMed Web of Science ®Google Scholar
• Baker MB., Altman N.H, Podack E.R, Levy R.B. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645–2656
   PubMed Web of Science ®Google Scholar
• Braun M.Y, Lowin B., French L., Acha Orbea H., Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183: 657–661
   PubMed Web of Science ®Google Scholar
• Kang S.M, Schneider D.B, Lin Z., Hanahan D., Dichek D.A, Stock P.G, Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738–743
   PubMed Web of Science ®Google Scholar
• Allison J., Georgiou H.M, Strasser A., Vaux D.L. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci U. S. A. 1997; 94: 3943–3947
   PubMed Web of Science ®Google Scholar
• Kayagaki N., Yamaguchi N., Nagao F., Matsuo S., Maeda H., Okumura K., Yagita H. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci U. S. A. 1997; 94: 3914–3919
   PubMed Web of Science ®Google Scholar
• Dowling P., Shang G., Raval S., Menonna J., Cook S., Husar W. Involvement of the CD95 (APO-1/Fas) recep-tor/ligand system in multiple sclerosis brain. J Exp Med 1996; 184: 1513–1518
   PubMed Web of Science ®Google Scholar
• Giordano C., Stassi G., De Maria R., Todaro M., Richiusa P., Papoff G., Ruberti G., Bagnasco M., Testi R., Gal-Luzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997; 275: 960–963
   PubMed Web of Science ®Google Scholar
• Hueber A.O, Zomig M., Lyon D., Suda T., Nagata S., Ecan G.J. Requirement for the CD95 receptor-ligand pathway in c-myc-induced apoptosis. Science 1997; 278: 1305–1309
   PubMed Web of Science ®Google Scholar
• Seliger B., Hohne A., Knuth A., Bernhard H., Meyer T., Tampe R., Momburg F., Huber C. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 1996; 56: 1756–1760
   PubMed Web of Science ®Google Scholar
• Gabathuler R., Reid G., Kolaitis G., Driscoil J., Jefferies W.A. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 1994; 180: 1415–1425
   PubMed Web of Science ®Google Scholar
• Lebel M., Bertrand R., Mes Masson A.M. Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice. Oncogene 1996; 12: 1127–1135
   PubMed Web of Science ®Google Scholar
• Seliger B., Harders C., Wollscheid U., Staege M.S, Reske Kunz A.B, Huber C. Suppression of MHC class I antigens in oncogenic transformants : association with decreased recognition by cytotoxic T lymphocytes. Exp Hematol 1996; 24: 1275–1279
   PubMed Web of Science ®Google Scholar
• Yamit Hezi A., Plaksin D., Eisenbach L. c-fos and c-jun overexpression in malignant cells reduces their tumori-genic and metastatic potential, and affects their MHC class I gene expression. Oncogene 1994; 9: 1065–1079
   PubMed Web of Science ®Google Scholar
• Egle A., Villunger A., Marion K., Bock G., Gruber J., Auer B., Greil R. Modulation of Apo-1-induced programmed cell death in myeloma cells by Interferon alpha2. Eur. J. Immunol. 1996; 26: 3119–3126
   PubMed Web of Science ®Google Scholar
• Huang M., Sharma S., Mao J.T, Dubinett S.M. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996; 157: 5512–5520
   PubMed Web of Science ®Google Scholar
• O'Mahony A.M, O'Sullivan G.C, O'Connell J., Cotter T.G, Collins J.K. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 1993; 151: 4847–4856
   PubMed Web of Science ®Google Scholar
• Yagita M., Seppo A., Renkonen O., Saksela E. Dea-cetylase activity of human tumor cells producing immunosuppressive aminosugars: its possible role in resistance to cell-mediated cytotoxicity. Cancer Res 1993; 53: 5600–5604
   PubMed Web of Science ®Google Scholar
• Bergelson L.D. Gangliosides and antitumor immunity. Clin Investig 1993; 71: 590–594
   PubMedGoogle Scholar
• Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L, Schroter M., Burns K., Matt-Mann C., Rimoldi D., French L.E, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195
   PubMed Web of Science ®Google Scholar
• O'Connell J., O'Sullivan G.C, Collins J.K, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075–1082
   PubMed Web of Science ®Google Scholar
• Strand S., Hofmann W.J, Hug H., Muller M., Otto G., Strand D., Mariani S.M, Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion?. Nat Med 1996; 2: 1361–1366
   PubMed Web of Science ®Google Scholar
• Villunger A., Egle A., Marschitz I., Kos M., Boeck G., Ludwig H., Geley S., Kofler R., Greil R. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveilllance. Blood 1997; 90: 12–20
   PubMed Web of Science ®Google Scholar
• Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E, Schneider P., Bomand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363–1366
   PubMed Web of Science ®Google Scholar
• Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A.H, Nagata S. Fas ligand in human serum. Nat Med 1996; 2: 317–322
   PubMed Web of Science ®Google Scholar
• Friesen C., Herr I., Krammer H.P, Debatin K.M. Involvement of the CD95 (Apo-1/fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574–578
   PubMed Web of Science ®Google Scholar
• Hahne M., Renno T., Schroeter M., Irmler M., French L., Bornard T., MacDonald H.R, Tschopp J. Activated B cells express functional Fas ligand. Eur. J Immunol. 1996; 26: 721–724
   PubMed Web of Science ®Google Scholar
• Egle A., Kos M., Villunger A., Gruber J., Hittmair A., Lukas P., Grïnewald K., Greil R. Expression of Apo-1/fas (CD95), Bcl-2. Bax and Bcl-x in Myeloma cell lines: Relations to responsiveness to anti-Apo-1/fas mab and p53 functional status. Br. J. Haematol. 1997; 97: 418–428
   PubMed Web of Science ®Google Scholar
• Saas P., Walker PR., Hahne M., Quiquerez A.L, Schnuri-Ger V., Perrin G., French L., Van Meir E.G., de Tribolet N., Tschopp J., Dietrich P.Y. Fas ligand expression byastrocytoma in vivo: maintaining immune privilege in the brain?. J Clin Invest 1997; 99: 1173–1178
   PubMed Web of Science ®Google Scholar
• Niehans G.A, Brunner T., Frizelle S.P, Liston J.C, Salerno C.T, Knapp D.J, Green D.R, Kratzke R.A. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007–1012
   PubMed Web of Science ®Google Scholar
• Galle PR., Hofmann W.J, Walczak H., Schaller H., Otto G., Stremmel W., Krammer PH., Runkel L. Involvement of the CD95 (APO- 1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223–1230
   PubMed Web of Science ®Google Scholar
• Ortiz Arduan A., Danoff T.M, Kalluri R., Gonzalez Cua-Drado S., Karp S.L, Elkon K., Egido J., Neilson E.G. Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am J Physiol 1996; 271: F11193–201
   Google Scholar
• Richardson B.C., Lalwani N.D., Johnson K.J., Marks R.M. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol. 1994; 24: 2640–2645
   PubMed Web of Science ®Google Scholar
• Aggarwal B.B, Singh S., LaPushin R., Totpal K. Fas antigen signal proliferation of human diploid fibroblast and its mechanism is different from tumor necrosis factor. FEBS Lett 1995; 364: 5–8
   PubMed Web of Science ®Google Scholar
• Alderson M.R, Armitage R.J, Maraskovsky E., Tough T.W, Roux E., Schooley K., Ramsdell F., Lynch D.H. Fas transduced activation signals in normal human T lymphocytes. J. Exp. Med. 1993; 178: 2231–2235
   PubMed Web of Science ®Google Scholar
• Rathmell J.C, Townsend S.E, Xu J.C, Flavell R.A, Goodnow C.C. Expansion or elimination of B cells in vivo: dual roles for CD-40 and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319–330
   PubMed Web of Science ®Google Scholar
• Muzio M., Chinnaiyan A.M, Kischkel F.C, O'Rouke K., Shevchenko A., Ni J., Scaffidi C., Bretz J.D, Zhang M., Gentz R., Mann M., Krammer H.P, Peter M.E, Dixit V.M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95(Fas/Apo-1) death-inducing signaling complex. Cell 1996; 85: 817–827
   PubMed Web of Science ®Google Scholar
• Walker PR., Saas P., Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158: 4521–4524
   PubMed Web of Science ®Google Scholar
• Foote L.C, Howard R.G, Marshak Rothstein A., Rothstein T.L. IL-4 induces Fas resistance in B cells. J Immunol 1996; 157: 2749–2753
   PubMed Web of Science ®Google Scholar
• Bodmer J.L, Burns K., Schneider P., Hofmann K., Steiner V., Thome M., Bornand T., Hahne M., Schroter M., Becker K., Wilson A., French L.E, Browning J.L, MacDonald H.R, Tschopp J. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity 1997; 6: 79–88
   PubMed Web of Science ®Google Scholar
• Eischen CM., Schilling J.D, Lynch D.H, Krammer PH., Leibson P.J. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996; 156: 2693–2699
   PubMed Web of Science ®Google Scholar
• French L.E, Hahne M., Viard I., Radlgruber G., Zanone R., Becker K., Muller C., Tschopp J. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335–343
   PubMed Web of Science ®Google Scholar
• Iwai K., Miyawaki T., Takizawa T., Konno A., Ohta K., Yachie A., Seki H., Taniguchi N. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994; 84: 1201–1208
   PubMed Web of Science ®Google Scholar
• Suss G., Shortman K.A. subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 1996; 183: 1789–1796
   PubMed Web of Science ®Google Scholar
• Lee J., Richburg J.H., Younkin S.C, Boekelheide K. The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 1997; 138: 2081–2088
   PubMed Web of Science ®Google Scholar
• Liles W.C, Kiener P.A, Ledbetter J.A, Aruffo A., Klebanoff S.J. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429–440
   PubMed Web of Science ®Google Scholar
• Shiraki K., Tsuji N., Shioda T., Isselbacher K.J, Taka-Hashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U. S. A. 1997; 94: 6420–6425
   PubMed Web of Science ®Google Scholar
• Villunger A., Egle A., Kos M., Hartmann B.L, Geley S., Kofler R., Greil R. Drug-induced apoptosis is associated with enhanced Fas (CD95/Apo-1) Ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 1997; 57: 3331–3335
   PubMed Web of Science ®Google Scholar
• Nicoletti I., Migliorati G., Pagliacci M.C, Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 1991; 139: 271–279
   PubMed Web of Science ®Google Scholar
• Terstappen L., Johnson S., Segers-Nolten I., Loken M.R. Identification and characterization of plasma cells in normal human bone marrow by high resolution flow cytometry. Blood 1990; 76: 1739–1745
   PubMed Web of Science ®Google Scholar
• Matzinger P. The JAM test: A simple assay for DNA-frag-mentation and cell death. J. Immunol. Methods 1991; 145: 185–187
   PubMed Web of Science ®Google Scholar